Publicaciones científicas en Inglés. 2020
Tamargo J.
Selecting emergency therapy for patients with pre-eclampsia
Expert Opin Pharmacother. 2020 Mar 5:1-4. doi: 10.1080/14656566.2020.1727444. PMID: 32133877
González-Juanatey JR, Tamargo J, Torres F, Weisser B, Oudovenko N.
Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?
Rev Esp Cardiol (Engl Ed). 2020 Jan 23. pii: S1885-5857(19)30415-3. doi: 10.1016/j.rec.2019.11.008. PMID:
31983653. [Epub ahead of print]
Ruilope LM, Tamargo J, Ruiz-Hurtado G.
Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs
Eur Heart J. 2020 Jun 7;41(22):2067-2069. doi: 10.1093/eurheartj/ehaa487. PMID: 32498078
Hollan I, Ronda N, Dessein P, Agewall S, Karpouzas G, Tamargo J, Niessner A, Savarese G, Rosano G, Kaski JC, Wassmann S, Meroni PL.
Lipid management in rheumatoid arthritis: a position paper by the Cardiovascular Pharmacotherapy Working Group of European Society of Cardiology
Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):104-114. doi: 10.1093/ehjcvp/pvz033. PMID: 31397840
Tamargo J.
Treatment of Coronavirus Disease 2019: Shooting in the Dark
Eur Cardiol. 2020 Aug 10;15:e59. doi: 10.15420/ecr.2020.21. eCollection 2020 Feb. PMID: 32944088
Savarese G, Reiner MF, Uijl A, D Amario D, Agewall S, Atar D, Baumgartner I, Borghi C, De Carlo M, Drexel H, Kaski JC, Kjeldsen KP, Kucher N, Lund LH, Niessner A, Semb AG, Schmidt TA, Sulzgruber P, Tamargo J, Vitale C, Wassmann S, Aboyans V, Lewis BS.
Antithrombotic Therapy and Major Adverse Limb Events in
Patients With Chronic Lower Extremity Arterial Disease: Systematic Review and Meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases
Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):86-93. doi: 10.1093/ehjcvp/pvz036. PMID: 31392312
Tamargo J, Rosano G.
Low quality of some generic cardiovascular medicinal products represents a matter for growing concern
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):176-187. doi: 10.1093/ehjcvp/pvz037. PMID: 31501855
Tamargo J.
After a long time, the new ESC Guidelines for the management of patients with supraventricular tachycardia are here
Eur Heart J Cardiovasc Pharmacother. 2020 Jan 1;6(1):3-5. doi: 10.1093/ehjcvp/pvz068. PMID:
31800023
Kaski JC, Tamargo J, Savarese G.
Cardiovascular pharmacotherapy in older people: challenges posed by cardiovascular drug prescription in the elderly.
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):277-279. doi: 10.1093/ehjcvp/pvaa090. PMID: 32687147
El Hadidi S, Rosano G, Tamargo J, Agewall S, Drexel H, Kaski JC, Niessner A, Lewis BS, Coats AJS.
Potentially Inappropriate Prescriptions in Heart Failure with Reduced Ejection Fraction (PIP-HFrEF)
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 17:pvaa108. doi: 10.1093/ehjcvp/pvaa108. Online ahead of print. PMID: 32941594
Refoyo E, Troya J, Trigo E, Guzmán-Martinez G, Valbuena-López S, Caro-Codón J, Rosillo S, Moreno-Yanguela M, Tamargo J, Arribas JR, Acquatella H, Lopez-Sendon J.
Comparison of Noninvasive Cardiac Test Strategies for Newly Diagnosed Chagas Disease in a Non-Endemic Zone
Am J Trop Med Hyg. 2020 Jul 20. doi: 10.4269/ajtmh.20-0389. Online ahead of print. PMID: 32700660
Naccarelli GV, Bhatt DL, Camm AJ, Le Heuzey JY, Lombardi F, Tamargo J, Martinez JM, Naditch-Brûlé L; ARTEMIS AF Investigators.
Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies.
J Cardiovasc Pharmacol Ther. 2020 Sep;25(5):425-437. doi: 10.1177/1074248420926874. Epub 2020 Jun 5. PMID: 32500725
Tinaquero D, Crespo-García T, Utrilla RG, Nieto-Marín P, González-Guerra A, Rubio-Alarcón M, Cámara-Checa A, Dago M, Matamoros M, Pérez-Hernández M, Tamargo M, Cebrián J, Jalife J, Tamargo J, Bernal JA, Caballero R, Delpón E; ITACA Investigators.
The p.P888L SAP97 polymorphism increases the transient outward current (Ito,f) and abbreviates the action potential duration and the QT interval.
Sci Rep. 2020 Jul 1;10(1):10707. doi: 10.1038/s41598-020-67109-z. PMID: 32612162
Fontenla A, López-Gil M, Tamargo J, Matía-Frances R, Salgado-Aranda R, Rey-Blas JR, Miracle-Blanco A, Mejía-Martínez E, Pastor-Fuentes A, Toquero-Ramos J, Arias MA, Montilla M, Gómez de la Cámara A, Arribas F, en representación de los investigadores BRAKE-AF.
Ivabradine for chronic heart rate control in persistent atrial fibrillation. Design of the BRAKE-AF project
Rev Esp Cardiol (Engl Ed). 2020 May;73(5):368-375. doi: 10.1016/j.rec.2019.09.004. Epub 2019 Oct 17. PMID: 31631048
Fontenla A, Tamargo Menéndez J, López Gil M, Arribas F.
[Do we have a new drug for heart rate control in patients with permanent atrial fibrillation? Response]
Rev Esp Cardiol. 2020 Sep 9. doi: 10.1016/j.recesp.2020.08.004. Online ahead of print. PMID: 32921874
Alonso-Fernández-Gatta M, Gallego-Delgado M, Caballero R, Villacorta E, Díaz-Peláez E, García-BerrocaL B, Crespo-García T, Plata-Izquierdo B, Marcos-Vadillo E, García-Cuenllas L, Barreiro-Pérez M, Isidoro-García M, Tamargo-Menéndez J, Delpón E, Sánchez PL.
A rare HCN4 variant with combined sinus bradycardia, left atrial dilatation, and hypertrabeculation/left ventricular noncompaction phenotype.
Rev Esp Cardiol (Engl Ed). 2020 Sep 29:S1885-5857(20)30310-8. English, Spanish. doi: 10.1016/j.rec.2020.06.019. Epub ahead of print. PMID: 33008772.
|
